Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE-3 cardiovascular outcomes study of polyethylene glycol loxenatide in type 2 diabetes
ChiCTR2200056410Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoint: Time from randomization to first 3-point major adverse cardiovascular event. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200056410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056410.